Background Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the eff ect of azacitidine on overall survival compared with the three commonest conventional care regimens.
Introduction
Myelodysplastic syndromes are malignant diseases of bone-marrow stem-cells, characterised by ineff ective haemopoiesis leading to peripheral-blood cytopenias and, in many patients, progression to acute myeloid leukaemia.
1,2 Myelodysplastic syndromes are categorised morphologically with the French-American-British (FAB) and, more recently, WHO 3, 4 classifi cations. Individual prognosis is determined using the international prognostic scoring system. 5 Patients with myelodysplastic syndromes who had intermediate-2 or high-risk scores on the international prognosis scoring system (known as higher-risk myelodysplastic syndromes) have a median survival of 1·2 years or 0·4 years, respectively, 5 and a high-risk for progression to acute myeloid leukaemia. 5 Although increasing survival and suppression of leukaemic transformation are the primary goals of treatment, 6 no treatment strategies other than allogeneic stem-cell transplantation off er meaningful potential to change the natural history of the disease. [7] [8] [9] [10] [11] [12] [13] [14] [15] Results of a Cancer and Leukemia Group B (CALGB) trial comparing treatment with azacitidine, a DNA methyltransferase inhibitor, with best supportive care suggested improved overall survival with azacitidine, but the study was inconclusive because of its crossover design and absence of an active comparator. 16 This large, prospective, randomised, phase III, clinical trial was done to assess the eff ect of treat ment on overall survival with azacitidine. The control arm included the three most commonly used treatments in higher-risk myelodysplastic syndromes (best supportive care, lowdose cytarabine, or intensive chemotherapy). [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 17 
Methods

Patients
Patients were eligible for enrolment if they were aged 18 years or older, with higher-risk myelodysplastic syndromes (an international prognosis scoring system rating of intermediate-2 or high risk) and FAB-defi ned refractory anaemia with excess blasts, refractory anaemia with excess blasts in transformation, or chronic myelomonocytic leukaemia 3 with at least 10% bonemarrow blasts and a white-blood-cell count lower than 13×10⁹ cells per L. Patients needed an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and an estimated life expectancy of at least 3 months. Patients with therapy-related myelodysplastic syndrome, previous azacitidine treatment, or planned allogeneic stem-cell transplantation were excluded.
This phase III, international, multicentre, randomised, controlled, parallel-group, open-label trial was done in accordance with the Declaration of Helsinki. All patients provided written informed consent and the study was approved by the institutional review boards at all participating study sites. Enrolment to the trial and monitoring were done by site investigators and central pathology reviewers with standardised central review of all cytogenetic data.
Study design
Before randomisation, investigators determined which of the three conventional care treatments (best supportive care, low-dose cytarabine, or intensive chemotherapy) was most appropriate for each patient, with clinical judgment on the basis of age, ECOG performance status, and comorbidities (fi gure 1). Patients were then randomly assigned one-to-one to receive azacitidine or conventional care regimens (fi gure 2). No crossover was allowed, and use of erythropoietin or darbepoetin was prohibited.
Patients were stratifi ed by investigators according to FAB and international prognostic scoring system classifi cations. 3, 5 Randomisation was done centrally, with allocation by telephone; patients were assigned to treatment in blocks of four within each stratum. The randomisation sequence was computer generated independently by Pharmaceutical Product Development (Wilmington, NC, USA). An independent data-safety monitoring board reviewed safety data and did an unblinded review of a scheduled interim effi cacy analysis.
During the treatment phase of the trial, all treatments were continued until study completion (12 months after the last patient was assigned) or discontinuation due to relapse, unacceptable toxicity, or disease progression defi ned by the International Working Group (IWG 2000) criteria for myelodysplastic syndromes. 18 Azacitidine was given subcutaneously at 75 mg/m² per day for 7 days every 28 days (delayed as needed until blood-count recovery), for at least six cycles. Conventional care regimens were given as follows: best supportive care only (including blood product transfusions and antibiotics with granulocytecolony-stimulating factor for neutro penic infection); lowdose cytarabine, 20 mg/m² per day subcutaneously for 14 days, every 28 days (delayed as needed until blood-count recovery) for at least four cycles; or intensive chemotherapy (induction with cytarabine 100-200 mg/m² per day by continuous intravenous infusion for 7 days, plus 3 days of either intravenous daunorubicin [45-60 mg/m² per day], idarubicin [9-12 mg/m² per day], or mitoxantrone [8-12 mg/m² per day]). Patients who achieved complete or partial remission after induction (defi ned by the International Working Group criteria for acute myeloid leukaemia 19 ) received one or two consolidation courses with reduced doses of the cytotoxic drugs used for induction followed by best supportive care. All patients could receive best supportive care as needed. After treatment discontinuation, all patients were followed up until death or study completion.
Assessment of effi cacy and safety
Effi cacy analyses were by intention to treat. Safety analyses included all patients who received at least one dose of study drug and one or more safety assessments thereafter. The primary endpoint was overall survival, 
Statistical methods
This study was designed with 90% power-on the basis of a log-rank analysis-to detect an HR of 0·60 for overall survival in the azacitidine group compared with that in the conventional care group, with a two-sided α of 0·05. The protocol specifi ed that about 354 patients were to be randomly assigned over 18 months and then monitored for at least 12 months of treatment and follow-up, resulting in at least 167 deaths over the 30-month trial period. Recruitment and a minimum follow-up of at least 12 months for all patients, however, necessitated a longer study period. With a study period of 42 months and 195 deaths, the study had 95% power under the assumptions of the design. One interim analysis was done with an O'Brien-Fleming monitoring boundary with a Lan-DeMets α spending function to control the overall α at 0·05 (data not shown). 20 Overall survival was defi ned as the time from randomisation to death from any cause. Patients who remained alive were censored at the time of last followup. Time to transformation to acute myeloid leukaemia was measured from randomisation to development of 30% or greater bone-marrow blasts. Patients free from acute myeloid leukaemia transformation were censored for this analysis at the time of last adequate bone-marrow sample. Randomisation and analyses were stratifi ed on FAB subtype and international prognostic scoring system group. Time-to-event curves were estimated with the Kaplan-Meier method 21 and compared with stratifi ed logrank tests (primary analysis). Stratifi ed Cox proportional hazards regression models 22 were used to estimate hazard ratios (HRs) and associated 95% CIs. The primary analysis of overall survival between the azacitidine and combined conventional care groups used the stratifi ed Cox proportional hazards model without any covariate adjustments to estimate the HR. Cox proportional hazards regression with stepwise selection was used to assess the baseline variables of sex, age, time since original diagnosis of myelodysplastic syndrome, ECOG performance status, number of previous red-blood-cell transfusions, number of previous platelet transfusions, measurements of haemoglobin, platelets, absolute neutrophil count, and lactate dehydrogenase, bone-marrow blast percentage, and presence or absence of cytogenetic -7/del(7q) abnormality. The fi nal model included ECOG performance status, lactate dehydrogenase, haemoglobin, number of previous red-blood-cell transfusions, and presence or absence of the cytogenetic -7/del(7q) abnormality. Supportive overall survival analyses used the fi nal Cox proportional hazards model. The consistency of treatment eff ect across subgroups was assessed with the diff erence in likelihood ratio between the full model with treatment subgroup and treatment-by-subgroup interaction, and the reduced model without the interaction. Additional supportive effi cacy analyses by investigator preselection compared the azacitidine subgroups with the individual treatments that comprised conventional care (fi gure 1).
Haematological response, transfusion independence, and haematological improvement in the azacitidine and conventional care groups were compared with Fisher's exact test. The rate of infection requiring intravenous antimicrobials was calculated with the number of recorded infections treated with intravenous antimicrobials divided by the total number of patient-years of follow-up. The relative risk of infection was calculated as the rate of infection in patients taking azacitidine compared with the rate in those receiving conventional care. The MantelHaenszel estimate of the common relative risk, the associated 95% CI, and the test that it equals unity were calculated. 23 Analyses were done with SAS (version 9.13). This study is registered with ClinicalTrials.gov, number NCT00071799.
Role of the funding source
The principal investigator and leading coinvestigators designed and did the study, provided oversight for the analysis of the data by Celgene, and wrote the article in consultation with Celgene. Additionally, Celgene elicited independent review of the statistical analysis plan by Kenneth J Kopecky (Fred Hutchinson Cancer Research Center, SW Oncology Group Statistical Center, Seattle, WA, USA) and Gary G Koch (University of North Carolina at Chapel Hill, Director, Biometric Consulting Lab, Chapel Hill, NC, USA) and independent review of the analyses, interpretation of the results, and review of this paper by Gary G Koch. The corresponding author and coauthors had access to all the trial data and had fi nal responsibility for the decision to submit for publication.
Results
Between ) allogeneic transplantation during follow-up. Four patients in the azacitidine group and 14 in the conventional care group never received study drug but were followed for overall survival and are included in the intention to treat analysis (fi gure 2). All patients with protocol deviations are included in the intention to treat analysis.
Azacitidine was given for a median of nine cycles (IQR four to 15), and 151 (86%) of 175 of patients who received azacitidine remained on 75 mg/m² per day throughout the study with no dose adjustments. The median azacitidine cycle-length was 28 days (IQR 28-35); 862 (54%) of the 1611 cycle-lengths were 28 days, 413 (26%) 29-35 days, and 336 (21%) longer than 35 days. Low-dose cytarabine was given for a median of four and a half cycles (IQR two to eight); 59 (29%) of 201 cyclelengths were 28 days, 82 (41%) 29-35 days, and 60 (30%) longer than 35 days, the overall median was 35 days (IQR 28-36). Intensive chemotherapy was given for a median of one cycle (IQR one to three), and best supportive care for a median 6·2 months (IQR 3·6-10·3).
At the time of last follow-up, 82 patients in the azacitidine group had died compared with 113 in the conventional care group. After a median follow-up of 21·1 months (IQR 15·1-26·9), median Kaplan-Meier overall survival was 24·5 months (9·9-not reached) in the azacitidine group compared with 15 months (5·6-24·1) in the conventional care group, a diff erence of 9·4 months (stratifi ed log-rank p=0·0001; fi gure 3). The HR for overall survival was 0·58 (95% CI 0·43-0·77). Kaplan-Meier survival curves for the azacitidine and conventional care groups separated permanently after about 3 months, at which time 140 (78%) of 179 patients receiving azacitidine had completed three cycles of treatment (fi gure 3). At 2 years, on the basis of KaplanMeier estimates, 50·8% (95% CI 42·1-58·8) of patients in the azacitidine group were alive compared with 26·2% (18·7-34·3) in the conventional care group (p<0·0001).
The supportive analysis of all predefi ned sub groups of patients showed consistency of the azacitidine eff ect on overall survival compared with conventional care (fi gure 4). In particular, overall survival was better for azacitidine than conventional care in all the cyto genetic subgroups on the international prognosis scoring system (poor prognosis HR 0·53, 95% CI 0·32-0·87, p=0·012; intermediate prognosis 0·44, 0·22-0·88, p=0·021; and good prognosis 0·59, 0·37-0·92, p=0·021). In patients with -7/del(7q), median Kaplan-Meier overall survival was 13·1 months (IQR 3·9-24·5; 95% CI 9·9-24·5) in the azacitidine group (n=30) compared with 4·6 months (2·9-9·3; 3·5-6·7) in the conventional care group (n=27) giving an HR of 0·34 (95% CI 0·17-0·67, p=0·0017; fi gure 4). Additionally, sensitivity analyses exploring the eff ect of the eight patients who received allogeneic stem-cell transplantation included in the intention-to-treat analyses, determined they did not aff ect the signifi cance of the overall survival results (data not shown).
Similar to the primary overall survival comparison (azacitidine vs conventional care), results from the investigator preselection subgroup analysis of overall survival showed signifi cant diff erences favouring the study drug between azacitidine and best supportive care (9·6 months, p=0·0045) and azacitidine and cytarabine (9·2 months, p=0·0006). The diff erence in the comparison between azacitidine (n=17) and intensive chemotherapy (n=25), however, was not signifi cant (9·3 months, p=0·51, table 2).
Median time to acute myeloid leukaemia transformation was 17·8 months (IQR 8·6-36·8; 95% CI 13·6-23·6) in the azacitidine group compared with 11·5 months (4·9-not reached; 8·3-14·5) in the conventional care group (HR 0·50, 95% CI 0·35-0·70; p<0·0001). Results from the investigator preselection subgroup showed a signifi cant diff erence in time to acute myeloid leukaemia trans- formation for azacitidine versus best supportive care. Time to progression to acute myeloid leukaemia did not diff er signifi cantly in the comparisons of azacitidine with either low-dose cytarabine or intensive chemotherapy (table 2) . The proportion of patients with complete and partial remission was signifi cantly higher in the azacitidine group than in the conventional care group (table 3). In the investigator preselection analysis, the proportion of patients with complete remission on azacitidine was signifi cantly higher than with either best supportive care or low-dose cytarabine but not higher than with intensive chemotherapy (table 3) . The proportion of patients with partial remission with azacitidine was higher than that with best supportive care, but no higher than with the other two treatments. Time to disease progression, relapse after complete or partial remission, and death were signifi cantly longer in the azacitidine group (median 14·1 months, IQR 4·2-27·6) than in the conventional care group (8·8 months, 3·8-not reached; log-rank p=0·047). The proportions of erythroid and platelet improvements were higher in the azacitidine group than in the conventional care group (table 3), but there was no signifi cant diff erence in the frequency of major neutrophil improvement between the two treatment groups. Duration of haematological response (complete and partial remission and any haematological improvement) was signifi cantly longer in the azacitidine group (median 13·6 months, IQR 5·9-26·4; 95% CI 10·1-16·3) than in the CCR group (5·2 months; 2·9-12·2; 4·1-9·7; logrank p=0·0002). Median duration of complete plus partial remission in the azacitidine group was 3·2 months (IQR 2·2-4·4; 95% CI 2·4-4·2) versus 3·0 months (2·1-4·0; 2·1-4·0; log-rank p=0·48) in the conventional care group. 50 (45%) of 111 patients (95% CI 35·6-54·8%) who were dependent on red-blood-cell transfusions at baseline in the azacitidine group became transfusion independent compared with 13 (11·4%) of 114 (6·2-18·7) in the conventional care group (p<0·0001).
The rate of infections treated with intravenous antimicrobials per patient year in the azacitidine group was 0·60 (95% CI 0·49-0·73) compared with 0·92 (0·74-1·13) in the conventional care group (relative risk 0·66, 95% CI 0·49-0·87; p=0·0032). There was a signifi cant interaction of treatment by investigator preselection for the rate of infection (p=0·0004). In the investigator preselection analysis, per-patient-year rates were similar when comparing azacitidine (0·66) and best supportive care (0·61; relative risk 1·09, 95% CI 0·74-1·65; p=0·69), but signifi cantly lower with azacitidine (0·44) compared with low-dose cytarabine (1·0; 0·44, 0·25-0·86; p=0·017) and with azacitidine (0·64) versus intensive chemotherapy (2·3; 0·28, 0·13-0·60; p=0·0059).
The most common grade 3-4 events were peripheral blood cytopenias for all treatments (table 4). The most common treatment-related non-haematological adverse events included injection site reactions with azacitidine, and nausea, vomiting, fatigue, and diarrhoea with azacitidine, low-dose cytarabine, and intensive chemotherapy. Treatment discontinuations before study completion in the azacitidine group compared with the conventional care group were mostly related to haematological adverse events (table 4). Table 4 lists the discontinuations because of haematological adverse events by investigator preselection.
During the fi rst 3 months of treatment, deaths occurred in 20 (11%) of 179 patients in the azacitidine group and 16 (9%) of 179 in the conventional care group (table 4) . These deaths were primarily attributed to underlying Data are number (%) or number/number with data (%). *3 months = 91 days. † Study completion defi ned as 12 months after the last patient was randomised. ‡National Cancer Institute's Common Toxicity Criteria toxicities based on laboratory data. Table 4 : Deaths, discontinuations, and grade 3 or 4 haematological toxicity by treatment group and investigator preselection disease (sepsis or bleeding) although four in the azacitidine group (two from sepsis and two from bleeding), and one in the conventional care group (receiving low-dose cytarabine) from cerebral ischaemia were probably related to treatment. Table 4 shows deaths in the fi rst 3 months of treatment by investigator preselection.
Discussion
Treatment with azacitidine prolongs overall survival and lowers the risk of progression to acute myeloid leukaemia in patients with higher-risk myelodysplastic syndrome com pared with treatment with conventional care regimens.
The previous CALGB trial 16 included a heterogeneous population of patients, best-supportive care as the only comparator, and a crossover design, and 53% of patients who received best-supportive care subsequently received azacitidine. Our study aimed to include only patients with higher-risk disease (87% were intermediate-2 or high on the international prognosis scoring system), and did not allow crossover. Furthermore, in the absence of a standard of care for the control regimen in higher-risk myelodysplastic syndromes, and with diff ering national, regional, institutional, or consensus guidelines, 24, 25 this trial compared azacitidine treatment with a control arm including the three most common treatments for higherrisk myelodysplastic syndromes over the past two decades (best supportive care, low-dose cytarabine, and intensive chemotherapy). [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 17 Randomisation allowed valid comparisons within investigator preselected subgroups. Patients enrolled in the study were representative of those with higher-risk myelodysplastic syndrome in demographic characteristics, presenting signs and symptoms, and subtypes on the FAB classifi cation. The proportions of patients selected to the best supportive care, low-dose cytarabine, and intensive chemotherapy groups were consistent with treatment practices (Germing U, Heinrich-Heine University, Dusseldorf, Germany, personal communication). 26 Median overall survival in the azacitidine group exceeded that in the conventional care group by 9·4 months with a 2-year survival rate that was nearly doubled. The survival benefi t with azacitidine was seen across all prognostic subgroups analysed, including those patients with poor, intermediate, and good cytogenetics according to the international prognosis scoring system. Patients with numerical or structural abnormalities of chromosome 7, who have a particularly poor outcome with traditional management strategies, 17, [27] [28] [29] had overall survival improvement with azacitidine.
The survival advantage in the azacitidine group was observed early in the treatment course compared with the conventional care group, with separation of the Kaplan-Meier survival curves occurring after about 3 months of treatment, corresponding to completion of about three cycles of azacitidine treatment by most patients. The median number of azacitidine treatment cycles was nine, suggesting that long-term treatment might give the best survival benefi t.
Comparisons with the supportive investigator preselection analysis showed that treatment with azacitidine was associated with a signifi cant improvement in overall survival compared with low-dose cytarabine or best supportive therapy. Previous studies of low-dose cytarabine in high-risk myelodysplastic syndrome or acute myeloid leukaemia have reported low proportions of patients with response and poor survival, 30 particularly in patients with unfavourable cytogenetics. 17, 31, 32 A previous trial that compared treatment with one cycle of low-dose cytarabine with best supportive care showed no survival diff erences. 33 Although our trial was designed to maximise the potential of each treatment strategy by continuing treatment until evidence for disease progression, the median number of cycles with low-dose cytarabine was four and a half because of a combination of poor response, disease progression, and unacceptable toxicity.
The diff erence in median overall survival between the azacitidine and intensive chemotherapy groups was not statistically signifi cant, possibly because of the small number of patients in this analysis. The proportion of patients with complete remission with intensive chemotherapy (40%) was in the range of published reports of myelodysplastic syndrome [9] [10] [11] [12] [13] [14] [15] and higher than that observed with azacitidine in this and the CALGB studies. 16 In patients who are candidates for allogeneic stem-cell transplantation and have a clear excess of marrow blasts (especially those with refractory anaemia with excess blasts in transformation, now classifi ed as acute myeloid leukaemia in the WHO classifi cation), intensive chemotherapy might be preferred to azacitidine before transplantation to provide better and more rapid reduction in marrow blast percentage. However, the value of reducing the blast percentage before transplantation in myelodysplastic syndromes is still disputed.
12
Furthermore, intensive chemotherapy is associated with high proportions of complete remission in myelodysplastic syndrome only in the absence of an unfavourable karyotype, 13, 14 and patients transplanted after failure of intensive chemotherapy have a very poor outcome after transplantation.
12 On the basis of results achieved with azacitidine in patients with unfavourable karyotype in the present study, this drug is being investigated before transplantation in patients with myelodysplastic syndrome with an excess of marrow blasts and unfavourable karyotype. 34 In the investigator preselection analysis, grade 3 and 4 neutropenia was more common in patients receiving azacitidine, low-dose cytarabine, and intensive chemotherapy than in those receiving best supportive care. Thrombocytopenia was also more common with azacitidine than with best supportive care, but less common than with low-dose cytarabine and intensive chemotherapy. Despite the higher frequency of thrombocytopenia and neutropenia observed with azacitidine compared with best supportive care, the frequency of haemorrhagic complications and infection was similar for both treatments. Risk of infection requiring intravenous antimicrobials was a third lower in the azacitidine group than in the conventional care group.
Finally, mechanisms of the activity of azacitidine in myelodysplastic syndromes are not fully known. Aberrant DNA hypermethylation has been implicated in the progression of myelodysplastic syndromes, and DNAmethyltransferase inhibitors, such as azacitidine, undo hypermethylation and restore normal transcription of tumour suppressor genes. 35, 36 Additional mechanisms of action of azacitidine in myelodysplastic syndromes are, however, probable, including a certain degree of tumour-cell apoptosis. Research to identify these mechanisms is underway. 35, 37, 38 This trial was international and multicentre in design with 79 investigative sites in 15 countries. In the comparison of azacitidine with the three most common treatments in higher-risk myelodysplastic syndromes, including two active treatments, treatment decisions were made in light of diff erent treatment practices infl uenced by regional, national, and local guidelines and consensus criteria. For these reasons, the results are applicable to the improvement of the treatment of myelodysplastic syndromes internationally. Ultimately, intensive chemotherapy might remain the appropriate treatment in some situations in higher-risk myelodysplastic syndromes, especially before allogeneic stem-cell transplantation in candidates for this procedure who have an excess of marrow blasts without an unfavourable karyotype.
Increased survival time is the primary goal of treatment for patients with higher-risk myelodysplastic syndromes. However, with the exception of allogeneic haemopoietic stem-cell transplantation, which is suitable for only a few patients with myelodysplastic syndrome, 27 no previous treatment strategies have shown a signifi cant overall survival benefi t. The results of this study indicate that azacitidine signifi cantly lengthens overall survival and changes the natural history of myelodysplastic syndrome in patients with higher-risk disease.
